Injectable testosterone suppresses natural production, causing infertility. New protocols use shorter-half-life oral/topical testosterone combined with enclomiphene (which blocks estrogen feedback) to increase T-levels while maintaining the body's own production, making it a viable option for younger men concerned about fertility.

For centuries, pharmaceuticals were derived from plants. Andrew Huberman, quoting Dr. Abud Bakri, reframes the peptide revolution as a new paradigm: 'mining the body' for medicine. Compounds like GLP-1 are naturally present, but when synthesized at high concentrations, they become powerful therapeutic agents.

High-profile individuals frequently combine GLP-1 agonists (for insulin sensitivity), growth hormone secretagogues, and androgen therapies (like TRT) to rapidly lose fat and gain muscle. This stack is behind many dramatic physical changes seen in CEOs and celebrities.

While GLP-1 has been a known target for a long time, the recent explosion in peptide therapeutics was primarily enabled by solving the historical challenge of poor half-life and exposure. Achieving one- or two-week half-lives through techniques like fatty acid acylation was the critical technological unlock for the field.

The dominance of peptides for GLP-1 therapeutics isn't a failure of antibodies but a success for picking the right tool. Peptides have a natural advantage when the therapeutic strategy involves engineering a natural ligand, making them a better starting point for certain targets like GPCRs.

The common misconception that GLP-1s cause muscle loss is incorrect at a cellular level. Research shows GLP-1 receptor agonists directly promote muscle protein synthesis. Muscle loss is a secondary effect of appetite suppression and inadequate protein intake, not a direct action of the drug itself.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

Peptides represent a shift from reactive sickness care to proactive human enhancement. Driven by the success of GLP-1s, the market will expand to include indications for sleep, muscle gain, skin, hair, and immunity, making them a daily staple for a majority of the population.

While sought for its muscle-building and anti-aging effects, growth hormone has a significant downside: it can induce insulin insensitivity, causing A1c levels to rise. This is a well-understood trade-off in the bodybuilding community, where you must get lean enough to handle taking growth hormone.